StateHouse Reports First Quarter 2024, Fourth Quarter 2023, and Full Year 2023 Financial Results

In This Article:

StateHouse Holdings Inc.
StateHouse Holdings Inc.

Q1 2024 Gross Margin Remains Strong at 46.5%

Gains in Cultivation Output and Market Share Amidst Successful Cost Reductions

Now Positioned as 4th Largest Cannabis Brand Operator in California

Kevin K. Albert Appointed to the Board of Directors

SAN DIEGO and TORONTO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc. (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, today announced its financial results for the three-month period ended March 31, 2024 (“Q1 2024”), and the three-month (“Q4 2023”) and twelve-month (“FY 2023”) periods ended December 31, 2023, as well as provided additional business updates. The unaudited condensed interim consolidated financial statements for Q1 2024, as well as the corresponding management’s discussion and analysis and the audited consolidated financial statements for FY 2023, as well as the corresponding management’s discussion and analysis, are available for download from the Company’s investor website, statehouseholdings.com, and on the Company’s SEDAR profile. The delay in filing arose as a result of the Company’s prior auditor unexpectedly discontinuing certain services to publicly traded companies and the subsequent engagement and onboarding of a new auditor, which involved the extensive review of prior financials, acquisitions and tax returns dating back to 2019 that has now been completed. Unless otherwise indicated, all dollar amounts in this press release are denominated in U.S. currency.

Q1 2024 Financial Highlights

  • Q1 2024 net revenues were $25.4 million, compared with $24.7 million in Q1 2023.

    • Retail revenues were $12.0 million representing 47.1% of total sales for Q1 2024, compared to $14.4 million or 47.2 of total sales in Q1 2023.

    • Branded wholesale manufacturing revenues were $11.5 million, representing 45.2% of total sales for Q1 2024, compared to $9.4 million or 38.3% of total sales in Q1 2023.

    • Cultivation revenues were $2.0 million, representing 7.7% of total sales for Q1 2024, compared to $0.8 million or 3.2% of total sales in Q1 2023.

  • Gross profit before adjustments for biological assets1 was $11.8 million in Q1 2024, compared with $10.9 million in Q1 2023.

  • Consolidated gross margins improved to 46.5% in Q1 20241, compared to 44.3% for Q1 2023.

  • Adjusted EBITDA1 improved to $0.8 million in Q1 2024 compared with Adjusted EBITDA1 loss of $2.4 million in Q1 2023.

Q4 2023 Financial Highlights

  • Q4 2023 net revenues were $25.1 million, compared with $25.5 million in Q4 2022.

    • Retail revenues were $13.0 million representing 51.8% of total sales for Q4 2023, compared to $16.4 million or 64.3% of total sales in Q4 2022.

    • Branded wholesale manufacturing revenues were $11.7 million, representing 46.5% of total sales for Q4 2023, compared to $8.6 million or 33.7% of total sales in Q4 2022.

    • Cultivation revenues were $0.4 million, representing 1.5% of total sales for Q4 2023, compared to $0.5 million or 1.9% of total sales in Q4 2022.

  • Gross profit before adjustments for biological assets1 was $10.4 million in Q4 2023, compared with $10.8 million in Q4 2022.

  • Consolidated gross margins1 declined to 41.6% in Q4 2023, compared to 42.4% for Q4 2022.